Close Menu


The letter cited the strain on non-COVID-19 care as laboratories struggle to meet demand for pre-procedure COVID-19 testing and other molecular tests.

The company's BD Veritor Plus SARS-CoV-2 assay, which has FDA Emergency Use Authorization, is designed to detect viral antigens in nasal swab specimens.

The funding package earmarks billions for the Public Health and Social Services Emergency Fund and Biomedical Advanced Research and Development Authority.

The tube, cap, and multitube consumables enable SARS-CoV-2 tests on its automated Panther and Panther Fusion sample-to-answer molecular diagnostic systems.

Along with the federal settlement, the company will also pay an additional $13.2 million to settle civil claims by different state attorneys general.

The new funding is being provided to nursing homes to address needs in the wake of the coronavirus pandemic, including increased SARS-CoV-2 testing.

The forum will gather information on issues surrounding SARS-CoV-2 testing and diagnostics from federal officials and the private sector.

The announcement follows a similar one from Becton Dickinson saying that HHS would buy its tests and platforms for coronavirus testing.

Even as the broader lab industry struggles to meet SARS-CoV-2 testing needs, many labs focused on nursing homes are unable to benefit from the demand.

Last month the agency said it had begun examining Medicare claims data to look for potential fraud in ordering of SARS-CoV-2 testing and related tests.